Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EBITDA (2016 - 2025)

Historic EBITDA for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to -$2.9 million.

  • Palisade Bio's EBITDA rose 1867.52% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2169.37%. This contributed to the annual value of -$14.9 million for FY2024, which is 1368.78% down from last year.
  • Palisade Bio's EBITDA amounted to -$2.9 million in Q3 2025, which was up 1867.52% from -$2.8 million recorded in Q2 2025.
  • Palisade Bio's 5-year EBITDA high stood at -$2.3 million for Q1 2021, and its period low was -$32.9 million during Q2 2021.
  • Over the past 5 years, Palisade Bio's median EBITDA value was -$3.6 million (recorded in 2022), while the average stood at -$5.0 million.
  • In the last 5 years, Palisade Bio's EBITDA crashed by 158419.74% in 2021 and then surged by 8912.9% in 2022.
  • Quarter analysis of 5 years shows Palisade Bio's EBITDA stood at -$3.0 million in 2021, then decreased by 27.59% to -$3.8 million in 2022, then grew by 18.04% to -$3.2 million in 2023, then fell by 7.23% to -$3.4 million in 2024, then increased by 13.6% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$2.8 million for Q2 2025, and -$2.3 million during Q1 2025.